roxy_nash said:

Beyond-use dating (BUD) for compounded supply compounded products: Lyophilized (unreconstituted): typically 6 months from compounding date…

Compounding pharmacy customer here with experience relevant to compounded supply.

I've ordered from 2 different compounding pharmacies over the past 2 years. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.

My current compounder (a 503B facility) has been consistently 98-101% purity across 10 orders. I pay $161/month vs $1,231 for brand. The savings are substantial and the product is equivalent in my experience.

Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.

TomTeleRx said:

Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…

Bookmarking. The distinction being drawn above is the one nobody else makes. Adding it to my notes with a link back to this thread.

roxy_nash said:

Beyond-use dating (BUD) for compounded supply compounded products: Lyophilized (unreconstituted): typically 6 months from compounding date…

Vendor communication red flags for compounded supply:

• Won't provide COA before purchase — walk away
• Claims "100% pure" without analytical data — unrealistic
• No physical address or phone number — accountability matters
• Pushes you to buy more than you need — pressure tactics
• Won't answer questions about their compounding process — transparency is key
• Payment only via crypto or wire transfer — legitimate pharmacies accept cards

A legitimate compounding pharmacy operates like a healthcare business, not a gray market dealer.

BrianDallas92 said:

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.

Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide still in shortage, tirzepatide removed from shortage list. This directly impacts compounding availability.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.